Sattar et al. [15] reported that Tirzepatide was not associated with increased risk of the MACE-4 outcome [HR = 0.80 (95% CI: 0.57-1.11)], cardiovascular death [HR = 0.90 (95% CI: 0.50-1.61)], MI [HR = 0.76 (95% CI, 0.45-1.28)], stroke [HR = 0.81 (95% CI, 0.39-1.68)] and hospitalization for unstable angina [HR = 0.46 (95% CI: 0.15-1.41)] when compared with the control groups (placebo, semaglutide 1 mg, dulaglutide 1.5 mg, insulin degludec, insulin glargine). The gene discussed is INS; the disease is stroke disorder.